Periollimel N 4 weeks

Adult administration

Recommended daily dosage - 0.16 g-0.35 g nitrogen per kg body weight (corresponding to 1 g-2 g amino acids per kg body weight) - Total energy 20-40 kcal per kg body weight - Total dosage of 20-40 mL per kg body weight or 1-1.5 mL per kcal consumed. Maximum daily dosage - 40 mL per kg body weight (corresponding to 1.0 g amino acids, 3.0 g glucose, 1.2 g fats per kg body weight). Infusion rate - The infusion rate should not exceed 3.2 mL/kg per hour (equivalent to 0.08 g/kg amino acids, 0.24 g/kg glucose, 0.10 g/kg fats per hour). 2. Children over 2 years - Dosage, nitrogen, and energy requirements decrease with age. - For patients aged 2-11 years, the limiting factor for daily dosage is magnesium concentration, and for hourly rates, lipid concentration. - For patients aged 12-18 years, the limiting factor for daily dosage is magnesium concentration, and for hourly rates, glucose concentration. - Usually, for younger children, a smaller dose is started and gradually increased to the maximum dose. 1) Children aged 2-11 years Maximum daily dosage - 45 mL per kg body weight (corresponding to 1.1 g amino acids, 3.4 g glucose, 1.4 g fats, total energy of 31.5 kcal). Infusion rate - The infusion rate should not exceed 4.3 mL/kg per hour (equivalent to 0.11 g/kg amino acids, 0.32 g/kg glucose, 0.13 g/kg fats per hour). 2) Children aged 12-18 years Maximum daily dosage - 45 mL per kg body weight (corresponding to 1.1 g amino acids, 3.4 g glucose, 1.4 g fats, total energy of 31.5 kcal). Infusion rate - The infusion rate should not exceed 3.2 mL/kg per hour (equivalent to 0.08 g/kg amino acids, 0.24 g/kg glucose, 0.10 g/kg fats per hour). 3. Method of administration and duration - Due to low osmolarity, this medication is infused via central or peripheral veins. It is preferable to administer over 12-24 hours. Intravenous nutritional supply may continue as necessary based on the patient's condition. - Generally, the infusion rate is gradually increased over the first hour post-initiation, adjusted considering the total infusion amount, daily dosage, and infusion time.

Child administration

1. Children from 2 to 11 years - Maximum daily dosage: 45 mL per kg body weight (corresponding to 1.1 g amino acids, 3.4 g glucose, 1.4 g fats, total energy of 31.5 kcal) -

This medication must be used according to the doctor's instructions, and it should not be taken arbitrarily without medical advice. If symptoms of anaphylactic reactions such as fever, chills, rash, or difficulty breathing occur during administration, the use should be immediately stopped and medical personnel should be informed. This medication may form precipitates when administered with intravenous calcium-containing preparations or with the antibiotic ceftriaxone, so do not use the same infusion equipment simultaneously. Especially in premature infants and low-birth-weight infants, the lipid component of this medication may not be metabolized properly, leading to elevated free fatty acid levels in the blood, and serious issues such as fat accumulation in pulmonary vessels may arise if administered to premature infants with serious respiratory diseases. Moreover, it should not be administered to specific patient groups such as preterm infants, newborns, children under 2 years of age, patients allergic to eggs, soybeans, peanuts, corn, patients with severe renal impairment or liver disease, and patients with amino acid metabolism disorders. In patients with renal failure, diabetes, liver dysfunction, or heart failure, which obscure fat metabolism, careful administration is required, and the internal fluid and electrolyte status must be stable prior to administration. Overdose or excessive infusion rates may cause adverse reactions such as sweating, fever, chills, headache, rash, difficulty breathing, so these symptoms should lead to immediate cessation of administration. During administration, regular monitoring of fluid and electrolyte balance, blood sugar, liver and kidney function, and coagulation status should be performed to detect any abnormalities. In patients with impaired fat metabolism, this medication may induce lipid overload syndrome, which may lead to liver dysfunction, anemia, coagulation abnormalities, requiring caution. Peripheral venous administration may cause thrombophlebitis, therefore the infusion site should be inspected daily, and if extravascular leakage occurs, administration should be stopped immediately and appropriate treatment should be received. Interactions may occur when this medication is mixed with or administered simultaneously with other drugs, so care should be taken when using it with calcium-containing products, ceftriaxone, ampicillin, etc. The safety for pregnant or breastfeeding women has not been established, so this medication should only be administered when the therapeutic benefits outweigh the risks. It should not be administered to children below the age of 2, and when administered to children over 2, pediatric formulations must be used, and vitamins and trace elements must be supplemented. Blood tests within 5-6 hours after administration may be affected by the lipid component of this medication, so the timing of testing should consider this point. In cases of overdose, symptoms like acidosis, excessive circulatory blood volume, vomiting, and headache may occur, and blood dialysis may be required as needed. Finally, this medication should not be used if its packaging is damaged, or if there is an abnormality in the solution, and the condition of the solution should be checked prior to administration.

Serious side effects

Anaphylactic reaction (fever, chills, rash, difficulty breathing), severe difficulty breathing, skin necrosis due to extravascular leakage, blisters, pulmonary embolism due to pulmonary vessel precipitates, difficulty breathing, yellowing of the skin or eyes (jaundice), extreme lethargy throughout the body, coma due to lipid overload syndrome, severe headache, seizures, altered consciousness, severe edema accompanied by elevated blood pressure, coagulation abnormalities, liver abnormalities (

Mild side effects

Sweating, fever, chills, headache, skin rash (erythematous, papular, pustular, macular, generalized rash), itching, flushing, tachycardia, loss of appetite, hypertriglyceridemia, abdominal pain, diarrhea, nausea, vomiting, hypertension, pain at the injection site, irritation, swelling/edema, erythema/warmth, skin necrosis, blisters, inflammation, sclerosis, skin tightness, thrombocytopenia, cholestasis, liver enlargement, increased alkaline phosphatase in the blood,

This medication should be stored in a sealed container to prevent air or moisture ingress. It should be stored at room temperature, taking care to avoid being too cold or freezing.

Appearance

A single transparent plastic bag containing a clear liquid, separated into three compartments by two membranes, with the amino acid solution and sugar solution being clear, colorless to light yellow, and the lipid solution being homogeneously cloudy.

Package unit

1000, 1500, 2000ml/bag